Literature DB >> 27631149

Effects of Direct-To-Consumer Advertising on Patient Prescription Requests and Physician Prescribing: A Systematic Review of Psychiatry-Relevant Studies.

Sara J Becker1,2,3, Miriam M Midoun2.   

Abstract

OBJECTIVE: To systematically analyze the effects of direct-to-consumer advertising (DTCA) on patient requests for medication and physician prescribing across psychiatry-relevant studies. DATA SOURCES: MEDLINE, PsycINFO, Thomson Reuters' ISI Web of Knowledge, and Google Scholar were searched (1999-2014) using variations of the terms direct-to-consumer advertising and psychiatric. Reference lists and an online repository of DTCA manuscripts were also scrutinized. STUDY SELECTION: English-language studies collecting data at the point of service, focusing on or including psychiatric medication, and assessing the effects of DTCA on patient and/or physician behavior were included. Of 989 articles identified, 69 received full-text review. Four studies across 5 manuscripts met inclusion criteria. DATA EXTRACTION: Data were extracted on participants, study design, methodological quality, and results. Methodological quality of individual studies was assessed using adapted criteria from the Effective Public Health Practice Project. Confidence in conclusions across studies was determined using principles from the well-established GRADE system.
FINDINGS: Due to lack of replication across strong randomized controlled trials (RCTs), no conclusions merited high confidence. With moderate confidence, we concluded that DTCA requests (1) are granted most of the time (1 RCT, 3 observational), (2) prompt higher prescribing volume (1 RCT, 1 observational), (3) promote greater adherence to minimally acceptable treatment guidelines for patients with depression (1 RCT), and (4) stimulate overprescribing among patients with an adjustment disorder (1 RCT).
CONCLUSIONS: Findings suggest that DTCA requests are typically accommodated, promote higher prescribing volume, and have competing effects on treatment quality. More methodologically strong studies are needed to increase confidence in conclusions. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27631149      PMCID: PMC5293137          DOI: 10.4088/JCP.15r10325

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  32 in total

1.  Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs.

Authors:  J J Davis
Journal:  J Health Commun       Date:  2000 Oct-Dec

2.  Direct-to-consumer advertising--strengthening our health care system.

Authors:  Alan F Holmer
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

3.  Criteria for the systematic review of health promotion and public health interventions.

Authors:  N Jackson; E Waters
Journal:  Health Promot Int       Date:  2005-09-16       Impact factor: 2.483

Review 4.  Direct-to-consumer advertising of pharmaceuticals.

Authors:  Ziad F Gellad; Kenneth W Lyles
Journal:  Am J Med       Date:  2007-06       Impact factor: 4.965

5.  Direct to consumer advertising of prescription drugs.

Authors:  Barbara Mintzes
Journal:  BMJ       Date:  2008-09-02

6.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

Review 7.  Effects of yoga on stress management in healthy adults: A systematic review.

Authors:  Cecilia S M Chong; Megumi Tsunaka; Hector W H Tsang; Edward P Chan; Wai Ming Cheung
Journal:  Altern Ther Health Med       Date:  2011 Jan-Feb       Impact factor: 1.305

8.  Recall bias in epidemiologic studies.

Authors:  S S Coughlin
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

Review 9.  Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis.

Authors:  Mary Leamy; Victoria Bird; Clair Le Boutillier; Julie Williams; Mike Slade
Journal:  Br J Psychiatry       Date:  2011-12       Impact factor: 9.319

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more
  5 in total

1.  User-informed marketing versus standard description to drive demand for evidence-based therapy: A randomized controlled trial.

Authors:  Sara J Becker; Sarah A Helseth; Tonya L Tavares; Daniel D Squires; Melissa A Clark; Valarie A Zeithaml; Anthony Spirito
Journal:  Am Psychol       Date:  2020-11

2.  Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, 2014-2017: Outcomes, Treatment Delivery, and Promising Horizons.

Authors:  Aaron Hogue; Craig E Henderson; Sara J Becker; Danica K Knight
Journal:  J Clin Child Adolesc Psychol       Date:  2018-06-12

3.  Association of State Policies Allowing Medical Cannabis for Opioid Use Disorder With Dispensary Marketing for This Indication.

Authors:  Chelsea L Shover; Noel A Vest; Derek Chen; Amanda Stueber; Titilola O Falasinnu; Jennifer M Hah; Jinhee Kim; Ian Mackey; Kenneth A Weber; Maisa Ziadni; Keith Humphreys
Journal:  JAMA Netw Open       Date:  2020-07-01

4.  Policies for Deprescribing: An International Scan of Intended and Unintended Outcomes of Limiting Sedative-Hypnotic Use in Community-Dwelling Older Adults.

Authors:  James Shaw; Andrea L Murphy; Justin P Turner; David M Gardner; James L Silvius; Zachary Bouck; Dara Gordon; Cara Tannenbaum
Journal:  Healthc Policy       Date:  2019-05

5.  Disseminating online parenting resources in the community during the COVID-19 pandemic: Lessons learned.

Authors:  Meagan Lasecke; Katerina Baeza-Hernandez; Gilly Dosovitsky; Amanda DeBellis; Brianna Bettencourt; Alayna L Park; Eduardo L Bunge
Journal:  J Community Psychol       Date:  2022-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.